References
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of randomised trials. Lancet 2005;365: 1687–1717
- Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;352:1451–1467
- Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients: Recommendations of the SIOG surgical task force. Eur J Cancer 2004; 40:926–938
- Muss HB. Factors used to select adjuvant therapy of breast cancer in the United States: An overview of age, race and socioeconomic status. Monogr Natl Cancer Inst 2001; 30:52–55
- Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550–556
- Adjuvant therapy for breast cancer. NIH Consensus Statement 2000 Nov 1–3; 17(4):1–35
- Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16: 1569–1583
- National Comprehensive Cancer Network. Breast cancer treatment guidelines version 2.2006, Available: http:// www.nccn.org via the INTERNET. Accessed 2005 Dec 12
- Naeim A, Keeler EB. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective? Breast Can Res Treat 2005;94:95–103
- Winer EP, Huddis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer: Status report 2004. J Clin Oncol 2005;23: 619–629